Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ralfinamide fixed-dose study in chronic neuropathic low back pain
2008-006176-30Phase 3Terminated
- Sponsor
- Newron Pharmaceuticals
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ralfinamide in neuropathic low back pain (NLBP) and Neuralgia (3 arms), sponsored by Newron Pharmaceuticals. Primary endpoint: Primary efficacy endpoint. Started Dec 2008; status: terminated.
02
Drugs
ralfinamide
03
Conditions
neuropathic low back pain (NLBP)Neuralgia
Beyond the preview
Go deeper on 2008-006176-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006176-30.